In some patients who completed a five-day course of Paxlovid, illness has been reported to reoccur between two and eight days after initial recovery from COVID-19. It’s characterized by a recurrence of symptoms or a new positive viral test after having tested negative. A brief return of symptoms may be part of the natural history of the virus in some patients, independent of Paxlovid treatment and regardless of vaccination status, according to the alert.
The agency said limited information is currently available from case reports on rebound COVID-19. There is currently no evidence that additional treatment is needed with Paxlovid or other therapies in cases where rebound is suspected.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
